Today at Sessions Late-Breaking Science LBS.04: From Intervention to Prevention: Advances in Coronary and Valvular Heart Disease 8-9:15 a.m. | Main Event I • Efficacy of Restrictive vs. Liberal Oxygenation in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement: A Randomized Clinical Trial (GLORIOUS) • Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement: A Randomized Clinical Trial (GLORIOUS) • Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: ENBALV Trial • The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine vs. Placebo and Spironolactone vs. Placebo in Patients With Myocardial Infarction: The Results of the Spironolactone Factorial LBS.05: Innovation in Prevention and Global Implementation 3:30-4:45 p.m. | Main Event I • TOPSPIN - A Three-Arm Randomized Trial for Treatment Optimization of Blood Pressure With Single-Pill Combinations In India • Electronic Nudges to Increase Influenza Vaccination Among Patients With History of Myocardial Infarction: Insights From 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU) • Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies After Acute Coronary Syndrome (ZODIAC) • Preliminary Results of Randomized Trial of New vs. Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low- and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Trial Featured Science FS.03: Getting Closer to the Summit: New HFpEF Treatments 8-9:15 a.m. | S100A • Effect of Finerenone on a Hierarchical Composite Endpoint Analyzed Using Win Statistics in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of FINEARTS-HF • Efficacy and Safety of Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified SexSpecific Analysis of the FINEARTS-HF Trial • Finerenone and Risk of Hyperkalemia in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) • Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights From the SUMMIT Trial Main Events Paul Dudley White International Lecture and Session 3:30-4:45 p.m. | S100A Environmental Crisis Exposome: Reshaping the Landscape of CV Basic Research and Health Care 8-9:15 a.m. | Main Event II GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics 9:45-11 a.m. | Main Event II SCIENTIFIC SESSIONS DAILY NEWS | Day 2 Sunday, Nov. 17, 2024 2 Meet the Trialist MTT.02 | Brain AF* 8–8:30 a.m. | Overflow Theater 2, North Building, Level 2 MTT.03 | GLORIOUS* 3:30–4:15 p.m. | Overflow Theater 2, North Building, Level 2 *Not a CE accredited session. Scan the QR code to view the Industry Programming Guide. Check the Mobile Meeting Guide app for updates. Paul Dudley White International Lecture and Session 3:30-4:45 p.m. | Main Event II “Atrial Cardiomyopathy and Ischemic Stroke: The Jury Is Out” Barbara Casadei, FRCP, FMedSci Claiming CE credit for #AHA24 #AHA24 attendees can receive up to 24.75 Continuing Education credits. CE credit claiming is limited to participation during the event Nov. 15-18, 2024. Complete the credit claim process within 30 days to avoid credit expirations. Log in a. Go to education.heart.org. b. Enter your username and password and sign in. c. Click on your name in the upper righthand corner and select My Library. Claim credit a. Click Start Survey to complete conference evaluation. b. Click Claim CE. c. Complete information and save. d. Your certificate is located in ‘My Account’ under ‘CE Details.’ Need assistance? For customer support, call 1-877-340-9899 (Monday-Friday between 8 a.m.-6 p.m. CST) or email education.help@email.education.heart.org.
RkJQdWJsaXNoZXIy MjI2NjI=